Oncolinx Pharmaceuticals LLC and the U.S. Department of Health and Human Services have presented new signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders, and bacterial and viral infections.